Vaxil Bio Ltd.VXL.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada

Vaxil Bio Ltd. is a Canadian biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product candidate is ImMucin, a MUC1 signal-peptide-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. Vaxil Bio also has pipeline candidates targeting COVID-19, tuberculosis, and monoclonal antibodies for oncology.

Key ratios

ROA

-16.1%TTM

2024 -14.3%2023 -12.6%2022 -19.1%

ROE

-13.4%TTM

2024 -22.2%2023 -25.1%2022 -41.2%

Track VXL.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer